Here are the latest studies that shed light on the effects of liraglutide and how it may be employed by scientists for further research
With the obesity epidemic contributing to rising rates of diabetes, heart disease and other chronic conditions, GLP-1 therapies represent a potential turning point in the fight against these diseases
Pioneer 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes
According to a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, a daily protein intake of 1.21.6 g/kg adjusted body weight, should be considered in individuals initiating GLP-1RA therapy, particularly when caloric restriction is prescribed
Since GLP-1 constipation is caused directly by the medication slowing gastric and intestinal motility, bowel function typically returns to baseline within 1-2 weeks of discontinuation